medic
literatur
descript
concurr
tuberculosi
tb
diabet
mellitu
trace
back
richard
morton
text
phthisiologia
suggest
associ
two
diseas
could
observ
earli
roman
time
nowaday
continu
develop
social
economi
dramat
chang
peopl
daili
diet
sharpli
increas
incid
diabet
worldwid
ottmani
et
al
time
tb
epidem
experienc
resurg
especi
develop
countri
past
two
decad
thu
result
increas
incid
combin
two
diseas
hassani
et
al
two
diseas
interact
caus
addit
clinic
problem
becom
new
challeng
tb
control
dooley
chaisson
diabet
major
risk
factor
peopl
infect
tb
develop
activ
diseas
sever
casecontrol
studi
shown
rel
odd
develop
tb
diabet
patient
rang
compar
nondiabet
patient
mboussa
et
al
coker
et
al
jabbar
et
al
shetti
et
al
diabet
also
common
clinic
complic
tb
patient
tb
patient
diabet
usual
risk
factor
treatment
failur
includ
higher
proport
smearposit
larg
number
void
patient
concurr
tb
diabet
also
increas
spread
tb
infect
thu
aggrav
tb
epidem
chronic
diabet
patient
almost
alway
develop
clinic
symptom
cardiovascular
nervou
urinari
immun
system
eventu
result
dysfunct
immun
system
metabol
disord
mani
studi
shown
abnorm
critic
cytokin
secret
includ
might
respons
nonspecif
immun
defici
diabet
patient
banerje
banerje
stalenhoef
et
al
alattiyah
mustafa
onset
tb
diseas
worsen
tb
infect
relat
immun
defici
dysfunct
stalenhoef
et
al
diabet
patient
longterm
exposur
high
blood
sugar
also
affect
white
blood
cell
abil
phagocytosi
exocytosi
electron
microscopi
em
studi
show
white
blood
cell
diabet
exhibit
less
protrus
deform
reduc
phagocytosi
lysosom
function
cytoplasm
organel
rare
seen
lower
function
abil
alveolar
macrophag
diabet
provid
favor
condit
replic
tb
pathogen
thu
increas
tb
suscept
diabet
patient
bronchoalveolar
lavag
fluid
tb
patient
diabet
alveolar
macrophag
h
product
significantli
lower
normal
factor
neg
correl
rang
lung
lesion
bacteria
quantiti
sputum
fat
metabol
disord
diabet
patient
often
accompani
hyperlipidemia
mean
level
triglycerid
higher
normal
one
triglycerid
metabol
product
glycerol
import
carbon
sourc
mycobacterium
tuberculosi
growth
reproduct
defici
protein
metabol
may
lead
hypoproteinemia
malnutrit
reduc
bodi
defens
capabl
repair
abil
mani
diabet
patient
also
experi
liver
dysfunct
reduc
convers
caroten
vitamin
result
airway
epitheli
cell
declin
defens
thicken
alveolar
epithelium
could
decreas
diffus
capac
increas
glycat
hemoglobin
conduc
oxygen
releas
tissu
lower
oxygen
content
increas
incid
tb
tb
advers
impact
diabet
well
tubercul
fever
increas
insulin
consumpt
burden
islet
cell
xie
time
chronic
consumpt
activ
tb
could
lead
islet
cell
malnutrit
decreas
function
dooley
chaisson
result
risk
peopl
develop
diabet
increas
exist
diabet
aggrav
acut
complic
diabet
ketoacidosi
may
induc
patient
diabet
pulmonari
tb
almost
alway
diabet
first
felek
et
al
incid
tb
higher
diabet
nondiabet
patient
main
onset
age
year
restrepo
et
al
diabet
patient
may
asymptomat
earli
stage
high
blood
sugar
occur
polydipsia
polyphagia
polyuria
weight
loss
symptom
appear
even
diabet
ketoacidosi
occur
sever
patient
offici
announc
diabet
diagnost
criteria
fast
plasma
glucos
fpg
level
mmoll
mgdl
oral
glucos
toler
test
ogtt
glucos
level
mmoll
mgdl
h
time
point
patient
symptom
high
blood
sugar
hisher
plasma
glucos
mmoll
mgdl
time
symptom
high
blood
sugar
one
criteria
fpg
ogtt
nonfast
plasma
glucos
level
check
american
diabet
associ
ad
glycosyl
hemoglobin
valu
diagnost
criteria
american
diabet
associ
patient
diabet
pulmonari
tb
specif
respiratori
symptom
may
symptom
tb
cough
sputum
fever
night
sweat
symptom
often
acut
onset
purul
sputum
hemoptysi
therefor
patient
diabet
pulmonari
tb
easili
misdiagnos
acut
pneumonia
pulmonari
suppur
lung
wet
rale
occur
extens
lesion
combin
infect
often
chest
xray
show
satur
exud
cheeselik
lesion
common
easili
fuse
form
caviti
spread
bronchu
lesion
site
common
prefer
site
tb
lung
lobe
well
rate
lower
lung
lobe
lesion
tb
higher
tbdiabet
patient
patient
tb
alon
caviti
format
common
tbdiabet
patient
fluid
level
occur
within
hollow
region
et
al
addit
rate
lower
lung
lobe
lesion
tb
caviti
format
increas
year
progress
sputum
smearposit
ratio
higher
tbdiabet
patient
without
diabet
mellitu
drugresist
dr
multidrugresist
mdr
patient
former
group
bashar
et
al
subhash
et
al
patient
diabet
mellitu
import
distinguish
infect
tb
pulmonari
infecti
diseas
diabet
suscept
gener
popul
infect
respiratori
diseas
like
pneumonia
acut
exacerb
chronic
bronchiti
marvisi
et
al
characterist
cough
sputum
fever
note
diagnosi
blood
sputum
pathogen
test
perform
imag
examin
sampl
taken
tumorsles
distinguish
tb
lung
bronchial
cancer
antitb
treatment
patient
tbdiabet
three
four
drug
isoniazid
inh
rifampin
rif
pyrazinamid
pza
ethambutol
emb
andor
streptomycin
sm
usual
appli
togeth
chemotherapi
program
gener
speak
take
year
complet
whole
cours
treatment
tb
longer
patient
pulmonari
tb
alon
drugresist
tb
confirm
even
longer
cours
requir
appropri
drug
accord
drug
suscept
test
scholar
believ
shortcours
chemotherapi
program
also
appropri
concurr
treatment
two
diseas
studi
shown
sputum
convers
rate
new
smearposit
patient
month
treatment
could
reach
sputum
convers
fail
patient
older
high
pretreat
smear
grade
andor
lung
field
lesion
two
lung
lobe
banu
rekha
et
al
present
random
control
studi
multicent
larg
number
sampl
standard
program
indic
specif
time
cours
treatment
thought
blood
glucos
control
key
point
treatment
patient
tb
diabet
patient
blood
glucos
control
good
excel
sputum
convers
rate
month
month
treatment
higher
whose
blood
glucos
poorli
control
zeng
et
al
differ
view
recurr
rate
pulmonari
tb
combin
diabet
higher
nondiabet
especi
patient
poor
glucos
control
treatment
diabet
comprehens
program
involv
health
educ
diet
exercis
medic
blood
glucos
monitor
aim
maintain
blood
sugar
within
standard
safeti
rang
avoid
reduc
incid
complic
specif
measur
could
refer
diabetesrel
treatment
guidelin
tb
patient
physic
statu
chronic
consumpt
requir
reason
calori
intak
highqual
protein
main
sourc
along
increas
intak
vitamin
dietari
fiber
could
improv
tb
site
repair
patient
hypoalbuminemia
take
special
care
increas
protein
intak
addit
daili
calori
requir
calcul
accord
patient
bodi
weight
activ
appropri
addit
energi
could
ad
increas
carbohydr
total
calori
consum
chines
diabet
societi
china
medicin
doctor
associ
nutrit
doctor
special
committe
studi
shown
plasma
concentr
antitb
drug
tb
patient
diabet
may
reduc
thu
reduc
effect
tb
treatment
nijland
et
al
ruslami
et
al
antitb
drug
impact
diabet
inh
interfer
normal
glucos
metabol
increas
sugar
urin
blood
increas
peripher
neuriti
well
rif
liver
enzym
induc
could
acceler
metabol
sulfonylurea
shorten
halflif
weaken
hypoglycem
effect
aminoglycosid
fluoroquinolon
harm
kidney
ethambutol
caus
optic
neuriti
drug
use
caution
clinic
patient
monitor
incid
diabet
increas
worldwid
becom
increasingli
import
control
treat
tb
effect
diabet
patient
prospect
studi
carri
improv
achiev
aim
earli
detect
earli
treatment
especi
develop
countri
silicosi
due
longterm
inhal
dust
contain
free
silica
extens
nodular
fibrosi
lung
tissu
main
characterist
barboza
et
al
three
clinic
form
chronic
silicosi
acut
silicosi
acceler
silicosi
chronic
acut
form
differ
clinic
manifest
signific
relationship
exposur
dust
concentr
level
silica
content
exposur
time
chronic
silicosi
common
clinic
form
silicosi
tb
correl
studi
shown
pulmonari
tb
incid
silicosi
patient
time
greater
normal
popul
incid
nonpulmonari
tb
time
greater
barboza
et
al
silicosi
patient
also
pleurisi
nt
know
exactli
patient
silicosi
easili
suffer
tb
tb
progress
correl
macrophag
effector
cell
cell
reactiv
cell
cellular
immun
system
silica
dust
cytotox
effect
lung
macrophag
caus
metabol
damag
pulmonari
macrophag
lead
macrophag
necrosi
recent
found
surfactantassoci
protein
spa
silicosi
bronchial
wash
fluid
lesur
et
al
spa
activ
alveolar
macrophag
inhibit
format
free
nitrogen
make
patient
suscept
tuberculosi
samten
et
al
addit
tuberculosi
may
escap
macrophag
phagocytosi
go
silica
nodul
activ
macrophag
swallow
silica
quickli
cell
lysosom
releas
collaps
cell
die
quickli
releas
mani
materi
could
stimul
fibroblast
result
pulmonari
capillari
bed
lymphat
system
serious
damag
blood
vessel
wall
thicken
deform
lumen
narrow
becom
occlud
reduc
blood
circul
lung
reduc
blood
suppli
weaken
lung
tissu
resist
tb
bacteria
pulmonari
lymphat
system
fibrosi
prevent
lymphat
system
resist
tuberculosi
invas
pathogenesi
silicon
tb
result
mani
factor
silica
dust
deposit
lung
destroy
cellular
immun
respons
tb
make
acquir
immun
tb
hard
establish
silicosi
patient
diagnosi
silicon
tb
includ
diagnosi
diseas
first
step
make
definit
diagnosi
silicosi
test
whether
combin
tb
somebodi
close
contact
silica
dust
clinic
manifest
imag
featur
analyz
make
comprehens
diagnosi
silicosi
sputum
smear
bacteria
cultur
reliabl
method
diagnosi
silicon
tb
gener
speak
sputum
bacteria
posit
rate
patient
silicon
tb
higher
due
high
caviti
incid
concern
easi
get
fals
neg
result
silicosi
extens
fibrosi
bronchial
distort
complic
discharg
tuberculosi
xie
therefor
bronchial
alveolar
fluid
balf
smear
tuberculosi
cultur
andor
bronchial
biopsi
use
diagnosi
necessari
silicosi
patient
may
tb
chest
xray
show
follow
sign
note
calvert
et
al
small
piec
asymmetr
shadow
uneven
densiti
apex
lung
sulcu
subclavian
arteri
silicon
nodul
upper
middl
lung
lobe
increas
significantli
short
period
time
nodul
profil
discern
variou
rang
size
densiti
sheet
asymmetr
shadow
indistinct
profil
uneven
densiti
connect
lung
hila
cablelik
shadow
drain
bronchu
shadow
bulk
significantli
increas
within
short
period
time
draw
back
toward
heart
lesion
spread
mainli
anterior
around
instead
vertic
direct
rib
big
irregular
caviti
form
short
period
lesion
dissemin
ipsilater
contralater
lumpi
shadow
unclear
outlin
extens
pleura
thicken
adher
local
pleural
effus
fluid
leakag
exclud
regular
antitb
treatment
month
abnorm
lung
shadow
significantli
improv
silicon
tb
distinguish
lung
diseas
variou
xray
pattern
similar
imag
lung
diseas
silicosi
node
distinguish
lung
cancer
metastat
lung
cancer
lumpi
silicon
tb
distinguish
lung
cancer
lumpi
silicon
tb
identifi
pure
bulk
lesion
distinct
made
silicosi
tb
caviti
pure
silicosi
caviti
pure
tb
caviti
silicon
tb
identifi
earli
phase
silicosi
identif
made
distinguish
silicon
tb
pneumonia
ehrlich
et
al
treatment
silicon
tb
includ
two
part
silicosi
treatment
tb
treatment
treatment
principl
silicosi
take
comprehens
measur
control
complic
aim
delay
progress
silicosi
reduc
patient
suffer
prolong
improv
qualiti
life
effect
drug
silicosi
progress
tb
faster
silicosi
activ
tb
even
promot
worsen
silicosi
control
therefor
main
program
silicon
tb
treatment
standard
tb
control
treatment
threeor
four
antitb
drug
chemotherapi
program
adopt
includ
inh
rif
pza
emb
sm
initi
phase
follow
continu
phase
case
mdrtb
individu
program
chemotherapi
combin
silicosi
treatment
map
base
patient
medic
histori
tb
drug
sensit
result
drug
use
togeth
least
kind
sensit
drug
whole
cours
treatment
last
month
program
perform
well
local
clinic
treatment
cours
silicon
tb
long
mani
type
medic
use
extra
attent
paid
drug
toxic
tb
chronic
lung
infect
clinic
treatment
patient
tb
combin
infect
straightforward
clinic
characterist
patient
sever
pulmonari
tb
long
durat
treatment
repeat
deterior
result
bronchial
pulmonari
structur
damag
lung
diseas
extens
alway
accompani
caviti
bronchial
lesion
bronchial
mucos
edema
granul
tissu
scar
stenosi
pulmonari
atelectasi
bronchiectasi
pleural
thicken
induc
secondari
pulmonari
infect
addit
diagnos
risk
factor
onset
age
tb
older
upper
respiratori
mucou
membran
cellular
immun
function
declin
impair
swallow
reflex
easili
lead
inhal
pathogen
dysfunct
airway
clearanc
elderli
experi
seriou
dysfunct
pulmonari
ventil
andor
pulmonari
air
exchang
could
induc
respiratori
failur
even
lead
death
get
pulmonari
infect
differ
type
tbrelat
lung
infect
classif
accord
differ
pathogen
clinic
characterist
involv
et
al
lung
structur
damag
caus
tb
includ
bronchiectasi
pulmonari
caviti
injuri
leav
patient
vulner
secondari
pulmonari
infect
complic
includ
empyema
bronchial
fistula
secondari
bacteri
infect
infect
gramneg
bacteria
especi
pseudomona
aeruginosa
aspergillu
anaerob
bacteria
significantli
increas
addit
number
nontubercul
mycobacteri
infect
combin
pulmonari
tb
increas
wang
infect
communityacquir
differ
gener
communityacquir
pneumonia
cap
underli
damag
lung
structur
hap
tb
inpati
caus
special
circumst
hospit
iatrogen
factor
tb
patient
especi
one
sever
pulmonari
tb
prone
get
hap
due
prolong
hospit
time
icu
respiratori
failur
receiv
mechan
ventil
incid
hospitalacquir
infect
pulmonari
tb
patient
higher
nontb
patient
chen
et
al
main
infect
area
lung
main
pathogen
gramneg
bacteria
especi
enterobacteriacea
escherichia
coli
klebsiella
pneumonia
enterobact
cloaca
serratia
proteu
etc
gglucos
nonfer
bacteria
p
aeruginosa
pseudomona
alcaligen
xanthomona
maltophilia
acinetobact
nitrateneg
bacilli
acinetobact
baumannii
bacteria
high
drug
resist
ineffect
antiinfect
treatment
infect
result
high
mortal
detect
rate
candida
spp
also
high
clinic
signific
controversi
chen
et
al
immunosuppress
lead
compound
infect
tb
mix
pathogen
gramposit
cocci
gramneg
bacteria
anaerob
bacteria
fungi
virus
pneumocysti
carinii
ap
refer
pulmonari
syndrom
caus
secret
mouth
throat
stomach
flow
throat
lower
respiratori
tract
small
amount
secret
inhal
lead
bacteri
aspir
pneumonia
larg
amount
acut
chemic
aspir
pneumonia
develop
aspir
pneumonia
major
risk
factor
lead
death
elderli
peopl
suffer
neurolog
cerebrovascular
diseas
radionuclid
tracer
scan
demonstr
communityacquir
pneumonia
elderli
caus
silent
aspir
kikuchi
et
al
pathogen
differ
patient
vari
gramneg
bacilli
includ
haemophilu
influenza
p
aeruginosa
k
pneumonia
stenotrophomona
maltophilia
e
coli
staphylococcu
aureu
common
continu
care
facilityacquir
aspir
pneumonia
ccfap
hospitalacquir
aspir
pneumonia
haap
patient
communityacquir
aspir
pneumonia
caap
patient
streptococcu
pneumonia
also
isol
sputum
addit
anaerob
bacteria
mainli
includ
bacteroid
peptostreptococcu
fusobacterium
also
import
kind
pathogen
ap
main
symptom
copd
aggrav
short
breath
alway
accompani
wheez
chest
choke
aggrav
cough
increas
sputum
product
increas
sputum
purul
andor
viscos
chang
sputum
fever
addit
symptom
whole
bodi
malais
insomnia
drowsi
fatigu
depress
mental
disord
could
also
appear
mani
factor
caus
aecopd
due
bacteria
h
influenza
pneumonia
moraxella
catarrhali
p
aeruginosa
gramposit
gramneg
bacteria
due
virus
influenza
parainfluenza
rhinoviru
coronaviru
adenoviru
respiratori
syncyti
viru
due
atyp
pathogen
rare
chlamydophila
pneumonia
mycoplasma
pneumonia
legionella
diagnosi
pulmonari
infect
usual
depend
comprehens
analysi
clinic
symptom
sign
peripher
blood
imag
data
pathogen
microbiolog
serolog
special
kind
infect
tb
pathogen
infect
symptom
sign
peripher
blood
imag
due
interfer
mouth
throat
bacteria
factor
pathogen
respiratori
tract
detect
posit
identifi
real
pathogen
infect
lower
respiratori
tract
therefor
diagnosi
tb
combin
pulmonari
infect
difficult
follow
aspect
heed
clinic
practic
symptom
cough
increas
sputum
purul
sputum
fever
appear
worsen
tb
hidden
lesion
tb
must
first
exclud
clinic
manifest
elderli
patient
pulmonari
infect
often
atyp
dyspnea
tachycardia
may
first
symptom
indic
combin
infect
imag
effect
tool
diagnosi
imag
characterist
valuabl
diagnosi
pulmonari
tb
combin
mycetoma
follow
imag
featur
often
suggest
addit
pulmonari
infect
tb
patient
level
emerg
liquid
tb
caviti
higher
infiltr
lesion
tend
absorb
prolif
chang
around
caviti
wall
increas
emerg
abscess
caviti
lesion
substanti
lesion
appear
besid
former
lesion
infiltr
shadow
fit
characterist
spread
along
bronchial
tube
condit
hemoptysi
caus
blood
blood
clot
gather
block
bronchial
alveoli
tb
combin
acut
respiratori
distress
syndrom
ard
pulmonari
edema
atelectasi
identifi
serolog
test
help
diagnosi
antigen
serolog
examin
mainli
use
diagnosi
atyp
pathogen
includ
legionella
mycoplasma
chlamydia
virus
procalcitonin
pct
test
help
distinguish
bacteri
infect
assay
betaglucan
test
help
diagnos
varieti
invas
fungal
infect
except
cryptococcosi
infect
caus
zygomycet
mucormycosi
phycomycosi
basidiobolomycosi
detect
galactomannan
gm
blood
contribut
diagnosi
aspergillosi
etiolog
diagnosi
import
guid
correct
effect
antibiot
clinic
pathogen
confirm
clinic
characterist
imag
figur
help
deduc
pathogen
offer
guid
treatment
bacteri
pneumonia
often
character
larg
amount
yellow
sticki
sputum
sputum
k
pneumonia
infect
brick
red
jellylik
sticki
similar
strawberri
jam
pneumonia
infect
character
rustlik
sputum
sputum
p
aeruginosa
pneumonia
green
characterist
smell
anaerob
bacteria
infect
sputum
sputum
pulmonari
amoeb
infect
brown
stench
candida
albican
infect
white
transpar
sputum
sticki
hard
cough
could
pull
wire
shape
xu
johnson
et
al
imag
imag
pneumonia
infect
uniform
densiti
distribut
lobe
segment
sublung
segment
pulmonari
tb
patient
coinfect
pathogen
often
slice
dotlik
shadow
aureu
infect
show
multipl
pulmonari
infiltr
lobar
segment
inflammatori
chang
begin
floccul
shadow
densiti
increas
appear
transluc
honeycomb
area
caviti
one
pneumatocel
appear
around
shadow
inflamm
area
could
increas
disappear
rapidli
short
time
accompani
pleural
effus
pneumothorax
bloodborn
infect
patient
mass
slice
bulklik
shadow
distribut
side
caviti
easili
form
earli
infect
k
pneumonia
appear
lobularli
invas
rapidli
expand
largelob
consolid
irregular
transluc
area
curv
bulg
often
appear
fissur
lobe
lobe
bulg
sign
thick
heavi
exud
h
influenza
infect
case
show
chang
characterist
bronchial
pneumonia
appear
lobular
segment
opaqu
shadow
p
aeruginosa
infect
lung
widespread
nodular
patchi
shadow
mainli
lower
lung
multipl
small
abscess
merg
togeth
form
larg
consolid
shadow
pneumonia
infect
found
divers
form
vagu
featheri
uniform
shadow
gener
shadow
close
lung
hila
thick
gradual
fade
along
lung
lobe
obscur
edg
lesion
movabl
shadow
patchi
slicelik
rickettsi
infect
patchi
shadow
emerg
consolid
shadow
uneven
densiti
distribut
segment
lobular
associ
small
amount
pleural
effus
featur
pulmonari
aspergillosi
aspergillomata
move
chang
bodi
posit
perform
chest
imag
test
pathogen
caus
lung
infect
includ
bacteria
fungi
virus
protozoa
common
inspect
method
includ
smear
observ
light
microscopi
cultur
identif
histopatholog
immunolog
molecular
biolog
techniqu
follow
point
attend
respiratori
specimen
collect
specimen
treat
quickli
exampl
rate
isol
pneumonia
aureu
gramneg
bacteria
reduc
specimen
store
room
temperatur
h
role
smear
examin
ignor
smear
pathogencaus
infect
pneumonia
h
influenza
acidfast
bacilli
nocardia
actinomycet
candida
cryptococcu
aspergillu
mucor
p
carinii
provid
inform
clear
probabl
diagnosi
even
definit
one
sampl
bronchu
fiber
mirror
brush
bronchoalveolar
lavag
fluid
balf
order
reduc
contamin
normal
flora
upper
respiratori
tract
quantit
cultur
result
import
concentr
bacteria
fungi
quantit
cultur
sputum
cfuml
pathogen
consid
lung
infect
pathogen
concentr
cfuml
regard
contamin
concentr
two
recultur
retest
recommend
concentr
cfuml
retest
show
result
bacteria
consid
infect
pathogen
sampl
bronchoscopi
artifici
airway
concentr
cfuml
indic
infect
pathogen
specimen
balf
concentr
cfuml
indic
infect
pathogen
sampl
brush
use
prevent
contamin
balf
employ
contamin
prevent
measur
quantit
concentr
cfuml
indic
infect
pathogen
woodhead
et
al
mani
method
detect
pathogeninduc
lung
infect
posit
result
consid
strongli
judg
limit
exist
technolog
normal
flora
contamin
varieti
pathogen
bacteria
grow
poorli
cfuml
sputum
cultur
medium
sputum
specimen
may
cultur
posit
normal
colon
bacteria
upper
respiratori
tract
streptococcu
viridan
staphylococcu
epidermidi
nonpathogen
neisseria
corynebacterium
diphtheria
none
diagnost
criteria
confirm
pathogen
diagnosi
section
met
diagnosi
unknown
pathogen
may
consid
choic
treatment
depend
natur
sever
infect
choic
antibiot
tb
patient
coinfect
cap
cap
patient
without
tb
long
bronchial
pulmonari
structur
damag
patient
bronchial
pulmonari
structur
damag
undergo
antitb
treatment
attent
paid
gramneg
bacteri
infect
antibiot
treatment
begin
soon
possibl
delay
treatment
sever
consequ
prognosi
close
relat
time
treatment
initi
take
first
dose
antibiot
within
h
diseas
onset
optim
lifethreaten
sever
pneumonia
suggest
use
broadspectrum
antibiot
earli
stage
pertin
deescal
therapi
appli
accord
pathogen
examin
patient
stabl
condit
antibiot
treatment
mild
sever
coinfect
recommend
chines
thorac
societi
detail
note
empir
antivir
treatment
recommend
patient
suspect
influenza
viru
infect
combin
antivir
therapi
use
highrisk
patient
typic
flulik
symptom
fever
myalgia
malais
respiratori
symptom
less
day
onset
may
also
use
prevent
influenza
epidem
period
tb
patient
coinfect
mild
pulmonari
infect
common
pathogen
pneumonia
pneumonia
h
influenza
c
pneumonia
suggest
antibiot
treatment
includ
penicillin
penicillin
amoxicillin
etc
macrolid
doxycyclin
first
second
gener
cephalosporin
diagnosi
sever
pneumonia
given
one
follow
disturb
conscious
respiratori
rate
timesmin
partial
pressur
arteri
oxygen
pao
mmhg
partial
pressur
arteri
oxygen
fraction
inspir
oxygen
ratio
pao
fio
mechan
ventil
treatment
requir
systol
blood
pressur
mmhg
concurr
septic
shock
xray
show
bilater
multilob
involv
lesion
expand
within
h
hospit
oliguria
urin
output
mlh
combin
acut
renal
exhaust
requir
dialysi
treatment
patient
treatment
depend
risk
factor
infect
p
aeruginosa
risk
factor
p
aeruginosa
infect
includ
structur
lung
diseas
bronchiectasi
pulmonari
cyst
diffus
bronchiol
use
glucocorticoid
prednison
mgday
past
month
broadspectrum
antibiot
use
day
malnutrit
number
neutrophil
peripher
blood
less
l
none
risk
factor
present
main
pathogen
pneumonia
aerob
gramneg
bacteria
l
pneumophila
pneumonia
h
influenza
aureu
antimicrobi
drug
combin
includ
third
gener
cephalosporin
combin
macrolid
inhibitor
amoxicillinclavulan
acid
ampicillinsulbactam
combin
macrocycl
lacton
carbapenem
combin
macrolid
risk
factor
p
aeruginosa
infect
main
pathogen
list
previous
plu
p
aeruginosa
antimicrobi
drug
includ
inhibitor
antipseudomona
activ
carbapenem
antibiot
combin
macrolid
aminoglycosid
necessari
antibiot
antipseudomona
activ
combin
intraven
inject
fluoroquinolon
suggest
antibiot
treatment
last
least
day
patient
normal
bodi
temperatur
maintain
h
one
kind
caprel
clinic
condit
end
treatment
initi
treatment
effect
concurr
outerpulmonari
infect
treatment
time
prolong
treatment
cours
differ
due
differ
pathogen
high
degre
varieti
complet
absorpt
shadow
lung
consid
standard
cessat
antibiot
ordinari
bacteri
infect
pneumonia
medic
stop
h
patient
maintain
normal
temperatur
sever
pneumonia
addit
complet
effect
time
appropri
antiinfect
treatment
nutrit
support
therapi
respiratori
secret
drainag
import
key
point
hap
initi
empir
antibiot
therapi
whether
patient
risk
factor
mdr
pathogen
infect
chines
thorac
societi
factor
includ
use
antibiot
past
day
hospit
day
longer
frequenc
antibiot
resist
higher
patient
treat
commun
medic
institut
risk
factor
health
careassoci
pneumonia
hcap
hospit
day
due
exacerb
infect
within
day
iv
therapi
administ
home
includ
antibiot
dialysi
continu
within
day
trauma
treatment
home
presenc
famili
member
infect
multidrugresist
pathogen
immunosuppress
diseas
andor
immunosuppress
therapi
patient
earli
onset
hap
ventilatorassoci
pneumonia
vap
hcap
risk
factor
mdr
pathogen
common
pathogen
includ
pneumonia
h
influenza
aureu
enterobacteriacea
e
coli
k
pneumonia
proteu
serratia
initi
empir
choic
antibiot
includ
ceftriaxon
levofloxacin
moxifloxacin
ciprofloxacin
ampicillinsulbactam
ertapenem
patient
risk
factor
mdr
pathogen
hap
vap
hcap
common
pathogen
includ
p
aeruginosa
k
pneumonia
produc
extendedspectrum
esbl
acinetobact
speci
bacteria
initi
empir
antibiot
antipseudomona
cephalosporin
cefepim
ceftazidim
carbapenem
imipenem
meropenem
inhibit
agent
piperacillintazobactam
antipseudomona
quinolon
ciprofloxacin
levofloxacin
aminoglycosid
amikacin
gentamicin
tobramycin
use
togeth
methicillinresist
aureu
mrsa
suspect
linezolid
vancomycin
ad
l
pneumophila
suspect
macrolid
fluoroquinolon
ad
hap
suspect
clinic
specimen
collect
bacteri
cultur
empir
antibiot
treatment
start
soon
possibl
h
later
combin
therapi
must
use
initi
treatment
mdr
pathogen
ensur
broadspectrum
coverag
reduc
possibl
inappropri
initi
empir
antibiot
therapi
note
patient
recent
use
one
kind
antibiot
one
avoid
empir
treatment
avoid
develop
antibiot
resist
treatment
must
base
local
antibiot
resist
situat
choos
drug
establish
appropri
empir
treatment
program
adequ
dose
antibiot
must
use
sever
hap
vap
patient
ensur
maximum
efficaci
chronic
obstruct
pulmonari
diseas
studi
group
chines
thorac
societi
adult
patient
good
renal
function
commonli
use
full
dose
follow
cefepim
ceftazidim
g
everi
h
meropenem
g
imipenem
g
g
piperacillintazobactam
g
ciprofloxacin
mg
amikacin
mgkg
daili
levofloxacin
mg
daili
patient
nt
chang
antibiot
past
h
stop
antibiot
drug
treatment
specimen
lower
respiratori
tract
cultur
neg
drug
adjust
made
accord
cultur
result
specimen
lower
respiratori
tract
clinic
effect
hap
vap
hcap
patient
receiv
appropri
initi
treatment
evid
infect
nonfer
gramneg
bacteria
complic
shortcours
treatment
day
recommend
initi
treatment
went
well
patient
respond
aminoglycosid
present
combin
drug
kind
medic
stop
day
numer
pathogen
infect
lung
immunocompromis
host
increas
opportun
special
pathogen
infect
result
special
pathogen
infect
virus
fungi
pneumocysti
jirovecii
close
monitor
addit
mycobacteria
bacteri
infect
acut
onset
nidu
day
local
alveolar
infiltr
main
infect
pathogen
bacteri
empir
antibiot
treatment
refer
cap
hap
program
describ
patient
present
diffus
pulmonari
alveoli
interstiti
infiltr
accompani
hypoxemia
occult
subacut
onset
p
jirovecii
may
caus
pathogen
prefer
treatment
sulfamethoxazol
mgkgday
trimethoprim
mgkgday
taken
oral
intraven
drip
gener
cours
treatment
day
caspofungin
use
treatment
ineffect
first
dose
mg
follow
mg
daili
slow
intraven
infus
specif
clinic
featur
cytomegaloviru
cmv
pneumonia
first
symptom
fever
cough
scanti
sputum
dyspnea
hypoxemia
main
imag
manifest
interstiti
pneumonia
character
nonconform
clinic
symptom
imag
perform
abnorm
imag
thicken
blur
lung
mark
earli
chest
xray
distinct
interstiti
pneumonia
appear
lung
activ
antiretrovir
therapi
clinic
symptom
improv
significantli
chest
xray
show
slow
absorpt
lesion
best
choic
ganciclovir
alon
combin
intraven
immunoglobulin
ivig
cmv
immunoglobulin
start
dose
ganciclovir
mgkg
time
day
day
day
addit
day
cours
treatment
usual
day
invas
pulmonari
mycosi
refer
acut
chronic
histolog
damag
caus
direct
colon
lung
bronchial
fungi
common
pathogen
candida
aspergillu
cryptococcu
neoforman
zygomycet
penicillium
marneffei
mainli
seen
southeast
asia
southern
china
candida
pneumonia
rare
antifung
treatment
gener
adopt
candida
cultur
sputum
typic
progress
invas
pulmonari
mycosi
follow
earli
period
day
inflamm
shadow
mistlik
ooz
around
shadow
halo
sign
caus
bleed
around
lesion
day
day
ga
chamber
consolid
inflammatori
lesion
visibl
air
bronchogram
day
day
lesion
develop
halfmoon
shape
transluc
zone
air
half
sign
caus
coagul
necrosi
pulmonari
embol
deterior
complet
necrosi
caviti
singl
onset
lesion
size
variabl
distribut
obviou
featur
drug
treatment
could
involv
voriconazol
itraconazol
caspofungin
micafungin
two
combin
necessari
imag
pulmonari
cryptococcosi
often
nodul
mass
shadow
pleural
unilater
bilater
lung
field
singl
multipl
onset
diamet
cm
smooth
edg
fuzzi
small
burr
often
caviti
form
wall
rel
smooth
uniform
neat
lowdens
shadow
nodular
shadow
imag
import
pulmonari
cryptococcosi
diagnosi
note
presenc
nodul
mass
smooth
lowdens
necrosi
area
caviti
especi
multipl
appear
usual
happen
patient
healthi
immun
system
contrast
main
progress
immunocompromis
host
show
parenchym
infiltr
hard
distinguish
pneumonia
caus
pathogen
amphotericin
b
flucytosin
use
togeth
fluconazol
use
treatment
treatment
cours
last
week
month
itraconazol
could
use
oral
patient
coinfect
mening
pulmonari
mucormycosi
case
import
symptom
diagnosi
hemoptysi
chest
pain
sign
earli
imag
show
bronchial
pneumonia
rapid
integr
larg
consolid
often
seen
form
caviti
wedgeshap
shadow
seen
bottom
near
pleura
larg
pulmonari
vessel
embol
valuabl
diagnosi
current
amphotericin
b
effect
medicin
clinic
dose
mgkgday
total
amount
g
cours
treatment
use
combin
flucytosin
p
marneffei
infect
penicilliosi
manifest
fever
anemia
skin
lesion
cough
hepatosplenomegali
gener
lymph
node
swell
specif
imag
often
misdiagnos
tb
amphotericin
b
use
treatment
switch
itraconazol
oral
therapi
week
later
immunesuppress
host
requir
longterm
use
itraconazol
possibl
aspir
pneumonia
consid
elderli
patient
histori
conscious
disord
difficulti
swallow
respiratori
symptom
follow
pulmonari
infiltr
shadow
diagnos
correctli
take
appropri
measur
swallowingimpair
patient
reduc
incid
aspir
pneumonia
follow
factor
use
evalu
oropharyng
dysphagia
clinic
abnorm
velopharyng
reflex
palat
reflex
pharynx
reflex
cough
eat
chang
sound
swallow
treatment
differ
accord
way
pneumonia
acquir
treatment
ccfap
hap
caap
consist
empir
treatment
program
describ
anaerob
treatment
consid
well
penicillin
combin
metronidazol
clindamycin
inhibitor
carbapenem
use
anaerob
treatment
gener
cours
treatment
day
time
could
prolong
day
even
week
month
patient
coinfect
necrot
pneumonia
lung
abscess
copd
symptom
exacerb
especi
aggrav
cough
purul
sputum
activ
antibiot
therapi
adopt
antibiot
select
base
patient
lung
function
common
pathogen
preval
pathogen
bacteria
drug
resist
area
taken
account
select
sensit
antibiot
cours
treatment
day
antibiot
indic
aecopd
antibiot
consid
case
copd
exacerb
three
princip
symptom
increas
sputum
volum
increas
sputum
purul
increas
short
breath
two
princip
symptom
one
increas
sputum
purul
patient
requir
mechan
ventil
either
noninvas
invas
risk
factor
p
aeruginosa
infect
copd
patient
risk
factor
p
aeruginosa
includ
recent
hospit
frequent
antibiot
treatment
histori
use
four
cours
antibiot
past
year
sever
copd
deterior
isol
p
aeruginosa
previous
acut
exacerb
period
contract
p
aeruginosa
clone
stabl
period
enterobact
spp
antimicrobi
drug
treatment
includ
intraven
inhibit
agent
secondgener
cephalosporin
cefuroxim
thirdgener
cephalosporin
ceftriaxon
cefotaxim
etc
respiratori
quinolon
levofloxacin
moxifloxacin
grade
iii
fev
predict
volum
grade
iv
fev
predict
volum
patient
chronic
respiratori
failur
copd
acut
exacerb
risk
factor
p
aeruginosa
infect
main
pathogen
includ
group
previous
describ
p
aeruginosa
bacteria
antimicrobi
drug
includ
intraven
inject
antibiot
ceftazidim
cefepim
piperacillintazobactam
cefoperazonesulbactam
imipenem
meropenem
antipseudomona
activ
aminoglycosid
quinolon
ciprofloxacin
etc
combin
necessari
drugresist
bacteri
infect
increas
drug
suscept
result
becom
import
choos
treatment
common
clinic
mdr
pathogen
p
aeruginosa
acinetobact
esblproduc
enterobacteriacea
mrsa
combin
therapi
mainli
use
combin
aminoglycosid
recommend
p
aeruginosa
aminoglycosid
replac
fluoroquinolon
mainli
ciprofloxacin
levofloxacin
effect
drug
acinetobact
treatment
includ
carbapenem
sulbactam
tigecyclin
polymyxin
b
e
isol
esblproduc
enterobacteriacea
thirdgener
cephalosporin
monotherapi
avoid
enterobact
bacteria
effect
drug
carbapenem
largescal
multicent
trial
prove
cur
effect
linezolid
vancomycin
equal
mrsa
treatment
patient
renal
insuffici
receiv
nephrotox
agent
linezolid
recommend
addit
inhal
antibiot
valuabl
adjuv
therapi
vap
caus
mdr
pathogen
cours
treatment
depend
patient
infect
pathogen
sever
degre
background
diseas
clinic
respons
treatment
antibiot
treatment
fail
mani
reason
patient
could
misdiagnos
andor
infecti
pathogen
misidentifi
secondari
infect
undetect
extern
sourc
infect
ventilatorrel
contamin
persist
medic
failur
occur
due
drug
resist
limit
due
advers
drug
reaction
andor
insuffici
respiratori
drug
concentr
due
drug
anatom
factor
pulmonari
infect
may
spread
outsid
lung
patient
immun
defens
may
caus
damag
includ
system
inflammatori
respons
lead
acut
lung
injuri
even
multipl
organ
failur
case
treatment
failur
follow
step
adopt
establish
reliabl
etiolog
diagnosi
refer
drug
sensit
andor
blood
concentr
develop
adjust
treatment
elimin
sourc
contamin
prevent
crossinfect
prevent
treat
elimin
factor
might
caus
aggrav
lung
injuri
respiratori
failur
physiolog
metabol
disord
syndrom
caus
pulmonari
ventil
dysfunct
andor
extern
diseas
tb
direct
reason
respiratori
failur
bodi
maintain
effect
ga
exchang
respiratori
failur
defin
patient
rest
breath
air
sea
level
pressur
arteri
oxygen
pressur
pao
lower
kpa
mmhg
without
carbon
dioxid
partial
pressur
paco
higher
kpa
mmhg
alway
process
respiratori
failur
develop
especi
chronic
respiratori
failur
respiratori
function
may
reduc
gradual
extern
respiratori
dysfunct
caus
elev
paco
decreas
pao
reach
standard
rest
blood
ga
valu
normal
obviou
clinic
symptom
pao
decreas
appar
paco
increas
physic
load
increas
state
often
call
respiratori
insuffici
pulmonari
tb
concurr
chronic
respiratori
failur
exacerb
acut
factor
coma
shock
lifethreaten
occur
report
patient
die
pulmonari
tb
respiratori
failur
die
transit
icu
lee
et
al
main
principl
treatment
tb
combin
respiratori
failur
includ
keep
respiratori
tract
unobstruct
correct
hypoxia
reduc
carbon
dioxid
retent
correct
acidbas
imbal
electrolyt
disturb
initiatingcontinu
antitb
therapi
treat
induc
factor
prevent
complic
support
good
nutrit
attent
paid
postur
basic
airway
manag
headtiltchinlift
jawthrust
maneuv
perform
prevent
tongu
fall
back
obstruct
airway
patient
lose
function
sputum
clear
clear
secret
mouth
pharynx
larynx
lower
respiratori
tract
import
bronchoscopi
use
remov
larg
amount
deep
accumul
secret
easi
expel
discharg
secret
increas
expector
use
patient
good
mucociliari
clearanc
pay
attent
airway
humidif
dilut
sputum
whether
sputum
easi
cough
aspir
sign
humidif
encourag
patient
cough
good
postur
promot
drainag
bronchi
expand
airway
inflamm
edema
reduc
drug
stimul
anticholinerg
agent
methylxanthin
may
chosen
accord
role
drug
treatment
respons
patient
recommend
aerosol
inhal
lung
airway
sever
occlud
intraven
inject
given
first
artifici
airway
built
nasotrach
intub
orotrach
intub
necessari
nasotrach
intub
usual
comfort
patient
airway
fix
easili
disadvantag
may
caus
nasosinus
tympan
advantag
orotrach
intub
set
easili
requir
less
equip
reduc
complic
improv
success
rate
recoveri
intub
recommend
patient
irregular
breath
choke
fall
coma
patient
requir
intub
week
tracheotomi
recommend
high
concentr
oxygen
may
given
grade
respiratori
failur
patient
increas
pao
rapidli
fio
adjust
begin
read
pao
target
mmhg
grade
ii
respiratori
failur
patient
adopt
control
oxygen
therapi
prevent
respiratori
depress
administ
oxygen
long
paco
increas
mmhg
patient
consciou
oxygen
concentr
may
increas
patient
receiv
longterm
oxygen
therapi
greater
h
daili
target
pao
mmhg
paco
increas
less
mmhg
import
pay
attent
advers
effect
oxygen
therapi
common
advers
reaction
includ
suppress
ventil
common
chronic
grade
ii
respiratori
failur
patient
oxygen
toxic
oxygen
toxic
affect
lung
injur
epitheli
cell
alveoli
caus
pulmonari
edema
central
nervou
system
manifest
trembl
convuls
seizur
recommend
patient
inhal
pure
oxygen
less
h
oxygen
use
less
day
oxygen
use
less
day
note
oxygen
content
inhal
air
increas
rapidli
absorb
blood
exchang
reduc
volum
nitrogen
remain
may
suffici
keep
lung
inflat
absorpt
atelectasi
occur
carbon
dioxid
retent
one
princip
pathophysiolog
chang
caus
alveolar
hypoventil
induc
seri
clinic
manifest
clinic
increas
amount
alveolar
ventil
effect
reduc
co
retent
howev
differ
pathophysiolog
basi
tb
patient
combin
respiratori
failur
strategi
measur
increas
ventil
differ
summar
applic
respiratori
stimul
controversi
may
worth
tri
sever
tb
case
especi
elderli
patient
bronchu
lung
structur
damag
andor
extens
lesion
caviti
bulla
mechan
ventil
kind
patient
may
lead
complic
higher
failur
rate
conserv
therapi
use
consciou
patient
hemodynam
stabl
paco
mmhg
oxygen
index
mmhg
paco
mmhg
blood
ph
valu
use
respiratori
stimul
secret
drainag
control
airway
spasm
notic
great
attent
paid
patient
conscious
paco
use
paco
drop
patient
lose
conscious
mechan
ventil
use
instead
mechan
ventil
technolog
import
clinic
tool
treatment
respiratori
failur
howev
tb
bulla
hemoptysi
consid
contraind
mechan
ventil
may
caus
spread
pulmonari
tb
make
treatment
difficult
studi
shown
among
patient
use
mechan
ventil
pulmonari
tb
combin
respiratori
failur
mortal
rate
similar
ard
twice
pneumonia
caus
respiratori
failur
lee
et
al
rolla
et
al
therefor
necessari
explor
set
effect
strategi
program
guid
applic
mechan
ventil
treatment
pulmonari
tb
respiratori
failur
mechan
ventil
either
invas
extern
noninvas
posit
pressur
ventil
nppv
mani
scholar
suggest
use
flexibl
select
scheme
patient
respiratori
failur
contraind
nppv
nppv
implement
accord
patient
respons
continu
halt
favor
invas
ventil
key
point
use
strategi
ration
master
indic
nppv
invas
ventil
well
chang
nppv
invas
ventil
nppv
wide
use
clinic
nt
requir
intub
incis
thu
avoid
complic
artifici
airway
nppv
also
reduc
need
sed
affect
normal
swallow
eat
talk
help
preserv
air
temperatur
humid
lung
minim
cough
also
use
intermitt
patient
taken
offlin
easili
clinic
effect
nppv
evalu
h
treatment
sign
clinic
improv
includ
paco
decreas
ph
oxygen
index
mmhg
alway
certain
percentag
failur
nppv
treatment
therefor
patient
improv
nppv
treatment
indic
endotrach
intub
prompt
emerg
intub
must
consid
addit
case
irrit
loss
conscious
inabl
clear
secret
toler
connect
method
hemodynam
instabl
oxygen
deterior
increas
carbon
dioxid
retent
intub
done
soon
possibl
sever
common
situat
tb
patient
respiratori
failur
ventil
strategi
xie
liu
physiolog
intens
care
medicin
group
chines
thorac
societi
sever
tb
patient
bronchial
pulmonari
structur
damag
often
extens
lung
lesion
caviti
bulla
etc
may
concurr
infect
patient
easili
lose
weight
malnourish
prone
respiratori
muscl
fatigu
meanwhil
often
compensatori
emphysema
socal
healthi
lung
tissu
addit
tb
bronchiectasi
pleural
thicken
often
combin
patient
elderli
may
tbassoci
chronic
obstruct
pulmonari
diseas
pulmonari
heart
diseas
sever
reason
respiratori
failur
pump
failur
thorax
pleural
chang
respiratori
muscl
fatigu
also
lung
failur
airway
obstruct
lung
tissu
lesion
pulmonari
circul
disord
mechan
respiratori
failur
includ
restrict
hypoventil
obstruct
hypoventil
increas
function
shunt
induc
part
pulmonari
alveoli
hypoventil
also
increas
function
dead
space
due
induct
pulmonari
alveoli
blood
hypoperfus
diffus
impair
anatom
shunt
increas
therefor
patient
usual
disturb
ventil
ventilatori
disord
show
type
ii
respiratori
failur
chronic
respiratori
failur
acut
exacerb
chronic
respiratori
failur
prefer
strategi
tri
adopt
conserv
noninvas
ventil
forc
antitb
treatment
begin
earli
possibl
effect
prevent
tb
lesion
spread
mechan
ventil
acut
phase
patient
receiv
longterm
home
nppv
therapi
need
noninvas
ventil
use
accord
patient
situat
long
patient
consciou
stabl
hemodynam
expector
independ
follow
condit
met
pao
mmhg
oxygen
index
mmhg
paco
mmhg
blood
ph
continu
posit
airway
pressur
cpap
mode
use
type
respiratori
failur
bilevel
posit
airway
pressur
bipap
mode
use
type
ii
respiratori
failur
initi
inspiratori
pressur
airway
pressur
ipap
rang
cmh
patient
longer
toler
expect
tidal
volum
mlkg
expiratori
pressur
airway
pressur
epap
gener
begin
cmh
oxygen
flow
adjust
maintain
transcutan
oxygen
satur
adjust
ipap
epap
time
accord
patient
situat
accord
patient
toler
ventil
time
set
h
time
three
four
time
day
accord
patient
toler
h
continu
applic
reach
reassess
patient
regularli
consid
repeat
arteri
blood
ga
analysi
mani
condit
suggest
noninvas
ventil
fail
switch
invas
ventil
requir
main
indic
failur
includ
respiratori
arrest
loss
conscious
apnea
sever
hemodynam
instabl
heart
rate
beatsmin
unconsci
andor
systol
blood
pressur
mmhg
requir
sedat
control
agit
secondari
failur
indic
breathless
increas
respiratori
rate
breathsmin
pao
mmhg
oxygen
index
mmhg
paco
increas
paco
mmhg
blood
ph
valu
chang
state
conscious
invas
mechan
ventil
condit
lung
protect
ventil
strategi
adopt
appli
ventil
lower
tidal
volum
maintain
airway
platform
pressur
cmh
use
mode
pressur
control
pressur
support
avoid
barotrauma
desir
paramet
tidal
volum
mlkg
respiratori
rate
breathsmin
inspiratori
flow
rate
lmin
oxygen
concentr
adjust
accord
arteri
blood
ga
analysi
result
expir
time
extend
inspiratorytoexpiratori
time
e
ratio
tri
maintain
airway
platform
pressur
cmh
posit
endexpiratori
pressur
peep
usual
cmh
longterm
use
immunosuppress
drug
caus
secondari
lung
infect
respiratori
failur
patient
critic
ill
rapid
diseas
progress
higher
mortal
rate
recommend
use
icu
exclus
nppv
respir
precis
adjust
inspir
oxygen
concentr
choos
oralnas
mask
better
seal
carri
noninvas
ventil
gener
invas
mechan
ventil
mode
recommend
facilit
onset
vap
bronchopleur
fistula
open
connect
bronchu
pleural
space
tb
patient
prone
suffer
bronchopleur
fistula
secondari
surgeri
primari
lung
structur
damag
pulmonari
barotrauma
mechan
ventil
mechan
ventil
use
take
kind
reason
measur
reduc
leakag
reduc
possibl
damag
implement
permiss
hypercapnia
strategi
appli
lower
respiratori
rate
lower
tidal
volum
higher
inspiratori
flow
lmin
reduc
inspiratori
time
lower
peep
patient
may
put
deep
sedat
even
muscl
relax
use
avoid
put
patient
posit
could
exacerb
leakag
use
minimum
chest
tube
attract
maintain
lung
expans
take
strong
measur
heal
expiratori
flow
obstruct
caus
bronchial
spasm
reason
measur
lung
ventil
thorac
drainag
cathet
plu
peep
use
necessari
nppv
prefer
treatment
aecopd
patient
support
respiratori
system
nppv
effect
tb
patient
aecopd
blood
ph
paco
mmhg
patient
paco
mmhg
ph
nppv
suggest
use
earli
stage
avoid
exacerb
ill
bipap
mode
recommend
cmh
dvalu
ipap
epap
improv
patient
alveolar
ventil
reliev
respiratori
muscl
fatigu
correct
hypercapnia
recommend
epap
level
cmh
maximum
less
cmh
aggrav
lung
dynam
hyperinfl
dh
patient
sever
aecopd
endotrach
intub
activ
use
invas
mechan
ventil
treatment
follow
case
ph
signific
hypoxemia
mmhg
hypercapnia
mmhg
unconsci
unstabl
hemodynam
larg
amount
airway
secret
andor
patient
toler
nppv
treatment
littl
remiss
h
nppv
treatment
principl
mechan
ventil
lower
tidal
volum
mlkg
slower
frequenc
timesmin
longer
expir
time
ie
paco
slightli
higher
normal
principl
peep
level
high
static
intrins
peep
allow
assist
ventil
psv
peep
simv
psv
peep
mode
adopt
soon
possibl
patient
condit
stabl
extub
usual
intub
day
execut
promptli
base
pulmonari
infect
control
respiratori
physiolog
paramet
order
effect
prevent
vap
ventilatordepend
copd
patient
stage
rehabilit
satisfi
follow
condit
nppv
treatment
appli
especi
night
accompani
fatigu
short
breath
lethargi
symptom
abnorm
ga
exchang
paco
mmhg
mmhg
sao
case
oxygen
appli
situat
continu
monitor
time
bad
effect
bronchodil
andor
hormon
oxygen
medic
treatment
patient
moder
sever
obstruct
sleep
apnea
unrespons
cpap
treatment
bronchial
asthma
pulmonari
tb
bronchial
asthma
patient
prone
tb
longterm
use
corticosteroid
respiratori
failur
often
relat
acut
sever
attack
asthma
routin
nppv
treatment
recommend
sever
asthma
patient
nppv
use
bronchial
asthma
patient
monitor
care
mechan
ventil
final
effect
mean
treat
sever
asthma
tb
patient
sever
asthma
patient
whose
main
symptom
sole
hypoxemia
applic
cpap
effect
reliev
respiratori
muscl
fatigu
improv
oxygen
applic
bipap
reliev
respiratori
distress
rapidli
promot
carbon
dioxid
emiss
improv
respiratori
function
invas
mechan
ventil
use
strategi
lower
tidal
volum
mlkg
lower
frequenc
timesmin
longer
expir
time
ie
sed
drug
requir
patient
coordin
treatment
peep
level
high
gener
cmh
accept
suffer
respiratori
acidosi
resolut
come
increas
ventil
inhal
small
amount
alkali
ph
main
reason
respiratori
acidosi
metabol
acidosi
lactic
acidosi
caus
hypoxia
treat
ventil
increas
oxygen
deliv
tissu
ad
appropri
amount
alkali
case
respiratori
acidosi
metabol
alkalosi
iatrogen
excess
ventil
diuret
symptom
low
potassium
low
chlorid
low
sodium
common
electrolyt
imbal
import
rememb
replenish
electrolyt
water
balanc
also
import
excess
fluid
intak
induc
aggrav
cardiac
insuffici
convers
insuffici
fluid
like
lead
sputum
drainag
problem
aggrav
airway
obstruct
mani
factor
could
induc
respiratori
failur
respiratori
tract
infect
treatment
pathogen
vari
accord
differ
basic
diseas
differ
risk
factor
differ
pathogen
microorgan
moreov
treatment
basic
diseas
also
import
patient
respiratori
failur
caus
sever
tb
bronchial
pulmonari
structur
damag
strong
antitb
treatment
earli
stage
effect
prevent
spread
mechan
ventil
could
directli
impact
prognosi
patient
goal
tb
patient
copd
mainli
treatment
chronic
airflow
obstruct
reduct
airway
inflamm
increas
secret
airway
patient
combin
bronchial
asthma
key
point
asthma
control
diuret
vasodil
could
use
appropri
heart
failur
cardiac
glycosid
must
use
cautious
applic
blocker
antiarrhythm
drug
avoid
arrhythmia
drug
could
impair
liver
function
avoid
affect
normal
applic
antitb
drug
complic
gastrointestin
bleed
shock
dic
treat
immedi
key
way
prevent
multipl
organ
failur
master
right
time
method
oxygen
therapi
mechan
ventil
improv
ventil
avoid
hypoxia
import
determin
treat
hypotens
promptli
avoid
organ
hypoperfus
also
note
tb
chronic
wast
diseas
tb
patient
respiratori
failur
easili
develop
anemia
correct
order
improv
blood
capac
oxygen
increas
oxygen
suppli
major
pulmonari
tb
patient
malnourish
make
activ
tb
progress
worsen
proteinenergi
malnutrit
usual
manifest
marasm
kwashiorkor
type
affect
structur
function
respiratori
muscl
reduc
ventilatori
drive
capabl
serious
affect
bodi
immun
defens
neg
impact
prognosi
tb
recurr
hard
heal
earli
stage
nonprotein
calori
low
may
increas
kcal
kg
situat
stabl
patient
sever
malnutrit
problem
offlin
calori
increas
accord
patient
toler
correct
hypoproteinemia
malnutrit
minimum
ratio
glucos
fat
calori
ratio
calori
protein
protein
intak
g
kg
tayek
kreymann
et
al
chen
et
al
grau
carmona
et
al
elk
et
al
vitamin
trace
element
ad
balanc
electrolyt
special
attent
element
could
affect
respiratori
muscl
function
potassium
magnesium
phosphoru
gastrointestin
disord
anorexia
tb
patient
reduc
nutrient
intak
result
anabol
reduct
meanwhil
tuberculosi
use
bodi
protein
metabol
caus
fever
night
sweat
weight
loss
consum
chang
lead
increas
catabol
decreas
fat
storag
loss
lean
bodi
mass
bodi
temperatur
increas
metabol
rate
increas
tan
li
nitrogen
amino
acid
could
get
lost
sweat
therefor
tb
patient
rel
higher
catabol
rate
energi
consumpt
higher
healthi
peopl
basal
metabol
rate
bmr
could
increas
sever
stress
catabol
rate
significantli
higher
anabol
rate
result
increas
protein
loss
muscl
tissu
loss
caus
skelet
muscl
atrophi
neg
nitrogen
balanc
caus
hypoproteinemia
decreas
immun
function
increas
infect
rate
mortal
glycometabol
anoth
metabol
disord
bodi
suffer
stress
symptom
includ
high
blood
sugar
decreas
glucos
oxid
util
rate
insulin
resist
increas
gluconeogenesi
meanwhil
energi
intak
reduc
histanoxia
develop
caus
increas
lactic
acid
lead
acidosi
among
tb
patient
malnutrit
calor
malnutrit
mix
malnutrit
protein
malnutrit
tan
et
al
weight
loss
main
characterist
tb
patient
increas
calor
intak
tb
chronic
wast
diseas
patient
requir
energi
healthi
peopl
gener
requir
kcal
kg
bodi
weight
total
intak
kcal
day
light
manual
labor
kcal
kg
bodi
weight
kcal
per
day
need
patient
need
protein
high
consumpt
also
due
benefit
protein
tissu
repair
lesion
heal
bodi
recoveri
tb
patient
need
intak
g
protein
per
kilogram
bodi
weight
daili
total
intak
g
day
highqual
protein
meat
poultri
seafood
egg
milk
soy
product
vitamin
b
c
supplement
first
vitamin
enhanc
bodi
immun
b
vitamin
could
improv
appetit
vitamin
may
reliev
side
effect
caus
use
isoniazid
vitamin
c
help
lesion
heal
hemoglobin
synthesi
vitamin
promot
calcium
absorpt
fresh
fruit
veget
main
sourc
vitamin
addit
milk
egg
offal
rich
vitamin
yeast
peanut
bean
lean
meat
rich
vitamin
calcium
iron
supplement
tb
patient
calcium
raw
materi
tb
calcif
patient
drink
g
milk
daili
contain
plenti
good
calcium
patient
hemoptysi
hematochezia
add
iron
essenti
raw
materi
hemoglobin
manufactur
summari
treatment
tb
patient
given
adequ
nutrit
enhanc
immun
function
reduc
neg
oxygen
balanc
order
repair
bodi
nutrit
therapi
mainli
focus
energi
protein
supplement
process
energi
supplement
pay
attent
ratio
sugar
fat
aggrav
liver
lung
burden
due
excess
sugar
combin
use
fat
emuls
glucos
could
provid
energi
therebi
reduc
protein
breakdown
energi
improv
nitrogen
balanc
branch
chain
amino
acid
essenti
amino
acid
suppli
enhanc
bodi
protein
level
reduc
albuminolysi
promot
nutrit
recoveri
diabet
mellitu
silicosi
lung
structur
damag
main
predispos
factor
pulmonari
tb
recurr
pulmonari
infect
weaken
bodi
immun
induc
pulmonari
tb
given
factor
diagnosi
treatment
pulmonari
tb
concurr
diseas
damag
critic
treat
two
diseas
togeth
cours
treatment
pay
attent
nutrit
support
reduc
occurr
complic
